Subscribe To
PSTV / Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
PSTV News
By Seeking Alpha
October 31, 2023
Plus Therapeutics, Inc. (PSTV) Q3 2023 Earnings Call Transcript
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q3 2023 Earnings Conference Call October 31, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President an more_horizontal
By GlobeNewsWire
September 11, 2023
Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference
AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical compa more_horizontal
By Seeking Alpha
August 14, 2023
Plus Therapeutics, Inc. (PSTV) Q2 2023 Earnings Call Transcript
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q2 2023 Earnings Conference Call August 14, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President and more_horizontal
By GlobeNewsWire
August 8, 2023
Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023
AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company more_horizontal
By GlobeNewsWire
August 3, 2023
Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
AUSTIN, Texas, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company more_horizontal
By GlobeNewsWire
May 25, 2023
Plus Therapeutics to Present at the 2023 Virtual June Investor Summit
AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company more_horizontal
By Seeking Alpha
April 20, 2023
Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript
Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript. more_horizontal
By Zacks Investment Research
April 20, 2023
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 p more_horizontal